Dr. Julia Oxford
Kleine Levin Syndrome (KLS), also known as Sleeping Beauty Syndrome, is characterized by progressive drowsiness and sleep for most days and nights. It is a rare neurological disorder with a prevalence of one to five cases per million. Those with KLS have recurring periods of excessive sleep, altered behavior, and a reduced understanding of the world. KLS primarily occurs in adolescents, boys more frequently than girls with a higher prevalence in Ashkenazi Jews. The exact cause of KLS is unknown but damage or malfunction of the hypothalamus may be involved. Although there is no definitive treatment for KLS, pharmaceuticals such as stimulants have been used to combat the sleepiness. However, these can cause irritability and mood swings, so alternatives to pharmaceuticals are also considered. Recent research suggests that a mutation in the gene LMOD3 may be the cause of KLS. LMOD proteins are structural proteins and appear to be developmentally regulated. In this poster, we will present the molecular mechanism for the disease and potential therapeutic targets for treatment on this disease.
Shusterove, Alexis (2020) Sleeping Beauty Syndrome - Lecture.srt (25 kB)
Shusterove, Alexis (2020) Sleeping Beauty Syndrome - Transcript.pdf (72 kB)
Shusterove, Alexis; Tubach, Aubrie; Rodriguez, Adriana; and Oxford, Julia, "Sleeping Beauty Syndrome" (2020). 2020 Undergraduate Research Showcase. 174.